Foxm1 inhibitors and their use in treating cancers

A compound having the structure:

• wherein,
• (Het)Ar is (hetero)aryl;
• R1 is:
• H or alkyl, e.g., C1-6 alkyl or C1-3 alkyl;
• R2 is:
• optionally substituted (hetero)aryl;
• R3 and R4 are independently:
• H, Me, Et, cyclopropyl, or R3 and R4 taken together are:
• —CH2CH2—O—CH2CH2—, —CH2CH2—N(H)—CH2CH2—, —CH2CH2—S—CH2CH2—, —CH2CH2—N(Me)-CH2CH2—, —CH2CH2—N(Et)-CH2CH2—, —CH2CH2—S(O)—CH2CH2—, —CH2CH2—S(O)2—CH2CH2—, —CH2CH2—N(H)—CH2CH2CH2—, or —CH2CH2—N(Me)-CH2CH2CH2—;
• and
• R5 and R6 are, independently, saturated or unsaturated (hetero)cyclopentyl having the structure
• where R7, R8, R9, and R10 are, independently, C, O, N, or S, optionally comprising one or two double bonds in the (hetero)cyclopentyl ring;
• or
• an amide bond, e.g.,
• an ester bond, e.g.
• or a pharmaceutically-acceptable salt thereof, including stereoisomers thereof and mixtures of stereoisomers thereof.